trending Market Intelligence /marketintelligence/en/news-insights/trending/u5qAoYbljefbnvt5IZUk2g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Australian regulator approves Endologix's abdominal aortic aneurysm treatment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Australian regulator approves Endologix's abdominal aortic aneurysm treatment

The Australian Therapeutic Goods Administration approved Endologix Inc.'s AFX2 Bifurcated Endograft System for inclusion on the Australian register of therapeutic goods.

The regulator has approved the use of AFX2 for the treatment of abdominal aortic aneurysms.

Endologix CEO John McDermott said the approval in Australia will allow the company to start offering the latest version of the anatomical fixation system to physicians and patients starting in 2017.